Clinical characteristics, parameters of disease activity and bone health.

<p>Mean ± SD, (range) are displayed. Followed by the number of patients examined if different from total number. (Pubic hair stage SDS (PH SDS), testicular volume/breast development stage SDS (TV/breast stage SDS), Lactate dehydrogenase (LDH), bilirubin (bili), reticulocytes (retic), 25-OH vitamin D (25-OH Vit D), 1,25-(OH)₂ vitamin D (1,25-OH Vit D), serum alkaline phosphatase (SAP), bone alkaline phosphatase (BAP), parathyroid hormone (PTH), urinary N-terminal telopeptide (NTX), urinary deoxypyridinoline (DPD), urinary calcium:creatinine ratio (Ca:Crea), osteocalcin, insulin-like growth factor 1 SDS (IGF-1 SDS), receptor activator of nuclear factor kappa-B (RANKL), osteoprotegerin (OPG) and dual-energy X-ray absorptiometry (DXA) Z-Score) were assessed. P-values refer to Kruskal Vallis test (HBSS vs Spherocytosis vs Healthy controls) if values are available for all 3 groups, or to Wilcoxon-two-sample test if values are available for HBSS and Spherocytosis only (in cursive).</p><p>Clinical characteristics, parameters of disease activity and bone health.</p

Serum levels of 25-OH vitamin D levels positively correlate with calcium to creatinine ratio in urine (<i>P</i> = 0.03, r = 0.36) in patients with hemolytic anemia.

<p>The predicted values based on bivariate regression are indicated as solid line.</p

Serum 25-OH vitamin D levels are significantly lower in patients who report bone pain (back pain and/or knee pain with exercise) than in patients without reported bone pain (left).

<p>Statistically significant differences between the groups, determined via Mann-Whitney test, are indicated with asterisks (*: <i>P</i><0.05).</p